Effect of novel antimicrobial blue light-emitting optical fiber on vancomycin-resistant <i>Enterococcus faecium</i> and carbapenemase-producing <i>Klebsiella pneumoniae</i>
Periprosthetic joint infections (PJIs), particularly those caused by multidrug-resistant organisms (MDROs), remain a major therapeutic challenge. Antimicrobial blue light (ABL) offers a promising non-antibiotic approach, inducing bacterial killing through photoexcitation of endogenous chromophores and subsequent reactive oxygen species generation. However, conventional single-point illumination systems are limited by uneven light distribution and poor penetration, restricting their use to superficial infections. We evaluated a novel isotropic optical fiber designed to overcome these geometric and optical constraints. The fiber was tested against vancomycin-resistant <i>Enterococcus faecium</i> (VR-Ef) and carbapenemase-producing <i>Klebsiella pneumoniae</i> (CP-Kp) in time-to-kill assays under low-power (20.1 mW mm<sup>-1</sup>) and high-power (40.3 mW mm<sup>-1</sup>) conditions over 60 min. Bacterial counts (CFU per mL) were determined at 0, 10, 20, 30, and 60 min. A one-way analysis of variance (ANOVA) with Tukey's post hoc test assessed time-dependent reductions; a two-way ANOVA evaluated the combined effects of illumination power and exposure time. ABL exposure resulted in time- and intensity-dependent bacterial reduction in both strains. Significant CFU reductions occurred from 30 min onward under high-power ABL (HP-ABL) and after 60 min under low-power ABL (LP-ABL) for both VR-Ef and CP-Kp ( <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>p</mml:mi> <mml:mo><</mml:mo> <mml:mn>0.001</mml:mn></mml:mrow> </mml:math> ). The two-way ANOVA revealed significant main and interaction effects of illumination power and exposure time (all <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>p</mml:mi> <mml:mo><</mml:mo> <mml:mn>0.001</mml:mn></mml:mrow> </mml:math> ). Although bactericidal thresholds ( <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mo>≥</mml:mo> <mml:mn>3</mml:mn> <mml:msub><mml:mi>log</mml:mi> <mml:mn>10</mml:mn></mml:msub> </mml:mrow> </mml:math> reduction) were not reached, bacterial killing increased markedly with higher power and longer exposure. This novel isotropic optical fiber enables uniform intraluminal ABL delivery, potentially extending blue-light therapy from superficial to deep surgical infections such as PJIs. Further optimization of illumination parameters and potential integration with photosensitizers may enhance its antimicrobial efficacy and clinical applicability.
Authors
- Santiago A. Lozano‐Calderón (ORCID: https://orcid.org/0000-0002-0681-9004)
- Barbara Körber-Irrgang
- Hilmar Wisplinghoff
- Antonia F. Chen (ORCID: https://orcid.org/0000-0003-2040-8188)
- Megan H. Goh
- Nathalie Jazmati (ORCID: https://orcid.org/0000-0003-4746-7970)
- Robert A. Rabiner
- Lucy L. Hederick (ORCID: https://orcid.org/0009-0008-4521-2257)
Institutions
- Providence Regional Medical Center Everett (US)
- Witten/Herdecke University (DE)
- Massachusetts General Hospital (US)
- Laboratory Dr. Wisplinghoff (DE)
- University Hospital Cologne (DE)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Journal of Bone and Joint Infection
- Published
- 2025-12-09
- DOI
- https://doi.org/10.5194/jbji-10-561-2025
- Citations
- 1
- Primary Topic
- Photodynamic Therapy Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.52